Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Pear Therapeutics logo — The leader in Prescription Digital Therapeutics

Pear Therapeutics

The leader in Prescription Digital Therapeutics

Founded 2013 United States Boston, United States 36 employees Post Ipo Equity Total: $409.00M Biotechnology, Digital Health +2

General Information

Company Name Pear Therapeutics
Founded Year 2013
Location United States Boston, United States +2
Founders / Decision Makers
Team member
Employees 36
Industries Biotechnology, Digital Health, Health and Wellness +1
Funding Stage Post Ipo Equity
Social

Get notified when Pear Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Pear Therapeutics

Pear Therapeutics is a leading company in the Prescription Digital Therapeutics industry. It is the parent company of Pear Therapeutics (US), Inc., traded on Nasdaq as PEAR. The company specializes in developing and commercializing software-based medicines known as prescription digital therapeutics (PDTs). With a vision to enhance patient outcomes, provide advanced engagement tools for clinicians, and offer cost-effective solutions for payers, Pear aims to redefine care through clinically validated software-based therapeutics. Moreover, Pear prides itself on having the first end-to-end platform for discovering, developing, and delivering PDTs, along with a robust pipeline of therapeutic products and candidates. Pear has successfully launched three PDTs with disease treatment claims recognized by the FDA. Its product, reSET®, designed for the treatment of substance use disorder, secured the distinction of being the first PDT to receive marketing authorization from the FDA for disease treatment. Subsequently, its second product, reSET-O®, developed for treating opioid use disorder, obtained Breakthrough Designation, further highlighting Pear's innovative capabilities. Additionally, Pear's third product, Somryst®, targeting chronic insomnia, became the first PDT to undergo simultaneous review through the FDA's Software Precertification Pilot Program and the traditional 510(k) pathway. Established in 2013, Pear Therapeutics is headquartered in the United States and operates within the sectors of Biotechnology, Digital Health, Health and Wellness, and Pharmaceutical. The company recently received a $125.00M Post-IPO Equity investment on 06 December 2021, with notable investors including Pilot House Ventures, Temasek Holdings, QUAD Investment Management, Sarissa Capital, SoftBank Vision Fund, TrustBridge Partners, The Eleven Fund, Shanda Group, Pritzker/Vlock Family Office, and Palantir Capital. For more information, visit Pear at www.peartherapeutics.com.

Taxonomy: digital therapeutics, prescription digital therapeutics, software-based medicine, FDA-approved PDTs, substance use disorder treatment, opioid use disorder treatment, chronic insomnia treatment, clinical validation, patient outcomes, clinician engagement, payer solutions, Nasdaq listed company, innovative healthcare solutions

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 10
Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		06 Dec 2021
Series D •••••• - 01 Mar 2021
Series D •••••• 10
Investor Investor Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		08 Dec 2020
Debt Financing •••••• 1
Investor
07 Jul 2020
Series C •••••• 9
Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		04 Jan 2019

View All 8 Funding Rounds

Latest News

View All
Biofourmis reaches unicorn status with $300M Series D — Mobihealthnews.com
Biofourmis reaches unicorn status with $300M Series D
Mobihealthnews.com Nov 23, 2025

Pear Therapeutics Alternatives & Competitors

Pear Therapeutics vs
AppliedVR
AppliedVR United States

Pioneering virtual reality therapeutics.

Series B
73 employees
Enterprise Software, Health Care
Compare Pear Therapeutics vs AppliedVR

FAQ About Pear Therapeutics

The leader in Prescription Digital Therapeutics
Pear Therapeutics was founded in 2013.
Pear Therapeutics is headquartered in Boston, United States.
Pear Therapeutics operates in the following industries: Biotechnology, Digital Health, Health and Wellness, Pharmaceutical.
Pear Therapeutics has approximately 36 employees.
Pear Therapeutics has completed 8 funding rounds, raising a total of $409.00M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Pear Therapeutics include AppliedVR. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Pear Therapeutics and AppliedVR are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Pear Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy